We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.
The phase III trial evaluated the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis. Per the company, this is the first phase III trial of a biologic in this patient population. The trial enrolled 251 patients who were 12 years to 17 years of age with moderate-to-severe atopic dermatitis and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable.
The results show that Dupixent monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients. The co-primary endpoint in international territories was 75% improvement in Eczema Area and Severity Index (EASI-75) at 16 weeks, while the same in the United States was the proportion of patients achieving Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). The trial results show that 41.5% of patients who received Dupixent every two weeks and 38% of patients who received Dupixent every four weeks achieved 75% or greater skin improvement (EASI-75) compared to only 8% with placebo (p less than 0.001). Moreover, 24% of patients who received weight-based dosing of Dupixent every two weeks (200 mg or 300 mg) and 18% of patients who received a fixed dose of Dupixent every four weeks (300 mg) achieved the primary endpoint of clear or almost-clear skin as compared to only 2% with placebo.
We remind investors that Dupixent is currently approved for use in certain adult patients with moderate-to-severe atopic dermatitis in the United States and Europe. The results from this trial in adolescents form the basis of regulatory submissions for an approval in treating adolescents as well.
We note that strong Dupixent sales drove Regeneron’s impressive second-quarter results. Label expansion of approved drugs will further boost sales. The company and partner Sanofi are also working to expand Dupixent’s label, which should diversify the company’s revenue base and reduce dependence on the lead drug. Dupixent is being studied in asthma, adolescent and pediatric atopic dermatitis, nasal polyps, eosinophilic esophagitis (EoE) and grass immunotherapy. Further, additional studies on the drug have been planned in 2018.
Last month, the FDA has approved a supplemental Biologics License Application (sBLA) for Eylea injection in patients with wet age-related macular degeneration (wet AMD). Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) .
Regeneron’s stock has gained 4.3% in the year so far against the industry’s 4.7% decline.
Regeneron is working to expand its portfolio. The company and partner Pharmaceutical Industries Ltd. (TEVA - Free Report) also announced positive top-line results from a phase III study on pipeline candidate, fasinumab in patients suffering from chronic pain from osteoarthritis (OA) of the knee or hip.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.
The phase III trial evaluated the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis. Per the company, this is the first phase III trial of a biologic in this patient population. The trial enrolled 251 patients who were 12 years to 17 years of age with moderate-to-severe atopic dermatitis and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable.
The results show that Dupixent monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients. The co-primary endpoint in international territories was 75% improvement in Eczema Area and Severity Index (EASI-75) at 16 weeks, while the same in the United States was the proportion of patients achieving Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). The trial results show that 41.5% of patients who received Dupixent every two weeks and 38% of patients who received Dupixent every four weeks achieved 75% or greater skin improvement (EASI-75) compared to only 8% with placebo (p less than 0.001). Moreover, 24% of patients who received weight-based dosing of Dupixent every two weeks (200 mg or 300 mg) and 18% of patients who received a fixed dose of Dupixent every four weeks (300 mg) achieved the primary endpoint of clear or almost-clear skin as compared to only 2% with placebo.
We remind investors that Dupixent is currently approved for use in certain adult patients with moderate-to-severe atopic dermatitis in the United States and Europe. The results from this trial in adolescents form the basis of regulatory submissions for an approval in treating adolescents as well.
We note that strong Dupixent sales drove Regeneron’s impressive second-quarter results. Label expansion of approved drugs will further boost sales. The company and partner Sanofi are also working to expand Dupixent’s label, which should diversify the company’s revenue base and reduce dependence on the lead drug. Dupixent is being studied in asthma, adolescent and pediatric atopic dermatitis, nasal polyps, eosinophilic esophagitis (EoE) and grass immunotherapy. Further, additional studies on the drug have been planned in 2018.
Last month, the FDA has approved a supplemental Biologics License Application (sBLA) for Eylea injection in patients with wet age-related macular degeneration (wet AMD). Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) .
Regeneron’s stock has gained 4.3% in the year so far against the industry’s 4.7% decline.
Regeneron is working to expand its portfolio. The company and partner Pharmaceutical Industries Ltd. (TEVA - Free Report) also announced positive top-line results from a phase III study on pipeline candidate, fasinumab in patients suffering from chronic pain from osteoarthritis (OA) of the knee or hip.
Zacks Rank
Regeneron currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>